Skip to main content

Table 2 Promising vaccine and antiviral drug development for the prevention and treatment of Ebolavirus

From: Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies

Treatment Efficacy Prophylactic Therapeutic Status References
Vaccines      
DNA vaccines Rodents and NHPs Yes Unknown Phase I clinical trails [57, 60]
Adenovirus Rodents and NHPs Yes Unknown Phase I clinical trails [62, 63]
rVSV-EBOV Rodents and NHPs Yes Yes Experimental [6568]
HPIV3-EBOV Rodents and NHPs Yes Unknown Experimental [70]
EBOV-VLPs Rodents and NHPs Yes Unknown Experimental [71]
Replication-deficient ZEBOV Rodents Yes Unknown Experimental [72]
Antivirals      
rhAPC Partial in NHPs Unknown Yes Licensed* [75]
rNAPc2 Partial in NHPs Yes Yes Phase II clinical trials [76]
FGI-103, FGI-104 and FGI-106 Rodents Yes Yes Experimental [8183]
Antisense oligonucleotides Rodents and NHPs Yes Yes Experimental [8588]
  1. *Licensed for the treatment of sepsis-induced coagulation disorders. The antithrombotic potential of rNAPc2 in orthopedic surgery and coronary revascularization was tested. Only FGI-106 was tested therapeutically. Abbreviations: HPIV3, human parainfluenza virus type 3; NHP, non-human primate; rhAPC, recombinant human activated protein C; rNAPc2, nematode anticoagulant protein c2; rVSV, recombinant vesicular stomatitis virus; VLP, virus-like particle.